Amgen's Phase 3 MariTide OSA trial status update: active, not recruitingSep 29Trial updateAmgenmaridebart cafraglutide
FDA approves label update for TEPEZZA; Amgen registers MariTide bioavailability studySep 23Weekly roundup, 2 itemsAmgenmaridebart cafraglutide
Amgen updates MariTide pipeline, discontinues AMG 513, keeps pressing FDA on TAVNEOSAug 4Quarterly updateAMG-513Amgen
Amgen posts results for three rocatinlimab Phase 3 trials, plus CodeBreak300 and AMG 133 updatesJul 24Weekly roundup, 5 itemsAmgenmaridebart cafraglutide
Amgen registers two Phase 3 extension trials for obesity drug maridebart cafraglutideJul 6Weekly roundup, 2 itemsAmgenmaridebart cafraglutide
Sign inSign in